An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) — Meletios A Dimopoulos (2017) | RDL Network
An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Meletios A Dimopoulos, Sebastian Grosicki, W Wiktor-Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Neeraj Gupta, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grząśko, Shaji Kumar
Shaji Kumar, Norbert Grząśko, Sossana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos
Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.